BioSpace News Archive

IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”) today announced that its ProSense System has received regulatory approval as a Class III device from the Brazilian Health Regulatory Agency (“ANVISA”).

Intensity Therapeutics, Inc. (Nasdaq: INTS) today announced that Lewis H. Bender, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, at 4:30 pm ET.

Synchron, the endovascular brain-computer interface company developing technology to restore functionality in patients with severe paralysis, announced completion of patient enrollment in the US-based COMMAND trial.

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will take part in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on September 13, 2023 at 3:35 p.m. ET.

Chimerix, a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced that management will participate in two upcoming investor conferences.

Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced that its Board of Directors has appointed Cynthia Pussinen as Chief Executive Officer and a member of the Board of Directors.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced the full launch of Axoguard HA+ Nerve Protector.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced that management will be participating in the following investor conferences.

Colorcon, a world leader in the development and supply of film coating systems, speciality excipients and functional packaging for the healthcare industries, announces the launch of a new Opadry® film coating system to address the moisture management needs for pharmaceutical tablets, without the use of titanium dioxide.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that the U.S. Patent and Trademark Office had issued a Notice of Allowance for a new opaganib patent covering sphingosine kinase 2 inhibition treatment for Ebola virus disease, supporting opaganib pro tection until October 2035.